To explore the possibility of using CYP19A1 as a target for sensitizing anti-PD-1 therapy, the effect of nanoparticle-encapsulated CYP19A1 siRNA on PD-1 blockade therapy was investigated in the orthotopic and subcutaneous colon cancer models. The gene discussed is CYP19A1; the disease is colonic neoplasm.